These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26786934)

  • 1. Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.
    Ganz PA; Petersen L; Bower JE; Crespi CM
    J Clin Oncol; 2016 Mar; 34(8):816-24. PubMed ID: 26786934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study.
    Ganz PA; Petersen L; Castellon SA; Bower JE; Silverman DH; Cole SW; Irwin MR; Belin TR
    J Clin Oncol; 2014 Nov; 32(31):3559-67. PubMed ID: 25267747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
    Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J
    Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
    Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
    Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.
    Sitlinger A; Shelby RA; Van Denburg AN; White H; Edmond SN; Marcom PK; Bosworth HB; Keefe FJ; Kimmick GG
    J Geriatr Oncol; 2019 Mar; 10(2):317-321. PubMed ID: 30553719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
    Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
    Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
    Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
    Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial].
    Volovăţ C; Volovăţ SR; Dogaru C; Vulpoi C
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):53-7. PubMed ID: 21688560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
    van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
    Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
    Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
    Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
    Whelan TJ; Goss PE; Ingle JN; Pater JL; Tu D; Pritchard K; Liu S; Shepherd LE; Palmer M; Robert NJ; Martino S; Muss HB
    J Clin Oncol; 2005 Oct; 23(28):6931-40. PubMed ID: 16157934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.